Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
20th January 2021 | David J Matlin | 2,426 | Grant/award etc. | $0.00 | |
29th December 2020 | Wtt Med Avail Ltd Abg | 45 | Open or private purchase | $14.00 | $630.00 |
29th December 2020 | Wtt Med Avail Ltd Abg | 55 | Open or private purchase | $14.00 | $770.00 |
28th December 2020 | Wtt Med Avail Ltd Abg | 3,894 | Open or private purchase | $13.98 | $54,424.88 |
28th December 2020 | Wtt Med Avail Ltd Abg | 3,213 | Open or private purchase | $13.98 | $44,906.82 |
17th December 2020 | Wtt Med Avail Ltd Abg | 6,946 | Open or private purchase | $13.12 | $91,132.21 |
17th December 2020 | Wtt Med Avail Ltd Abg | 5,731 | Open or private purchase | $13.12 | $75,191.29 |
17th December 2020 | Wtt Med Avail Ltd Abg | 1,248 | Open or private purchase | $14.00 | $17,472.00 |
17th December 2020 | Wtt Med Avail Ltd Abg | 1,029 | Open or private purchase | $14.00 | $14,406.00 |
16th December 2020 | Wtt Med Avail Ltd Abg | 12,851 | Open or private purchase | $13.06 | $167,848.20 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
MYOS RENS Technology, Inc. engages in the discovery, development, and commercialization of advanced nutrition products, functional foods, and other technologies. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk.